

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**  
Date of Report (Date of earliest event reported): **May 28, 2020**

---

**PROTAGONIST THERAPEUTICS, INC.**

---

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-37852**  
(Commission  
File Number)

**98-0505495**  
(IRS Employer  
Identification No.)

**Protagonist Therapeutics, Inc.**  
**7707 Gateway Blvd., Suite 140**  
**Newark, California 94560-1160**  
(Address of principal executive offices, including zip code)

**(510) 474-0170**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common Stock, par value \$0.00001	PTGX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07. Submission of Matters to a Vote of Security Holders**

At the Protagonist Therapeutics, Inc. (the “Company”) 2020 Annual Meeting of Stockholders (the “Annual Meeting”) held on May 28, 2020, the stockholders voted on the two proposals listed below. The proposals are described in detail in the Company’s definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 16, 2020. The results of the matters voted upon at the meeting were:

**Proposal 1** — To elect the two Class I directors named below to serve until the 2023 Annual Meeting of Stockholders. Each of the two named nominees was so elected, with the votes thereon at the Annual Meeting as follows:

Nominees	Final Voting Results		
	For	Withheld	Broker Non-Votes
Dinesh V. Patel, Ph.D.	16,515,423	1,916,749	3,542,396
Sarah Noonberg, M.D., Ph.D.	16,397,931	2,034,241	3,542,396

**Proposal 2** — To ratify the selection by the Audit Committee of the Board of Directors of the Company of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020. This proposal was approved by the requisite vote, with the votes thereon at the Annual Meeting as follows:

Final Voting Results			
For	Against	Abstain	Broker Non-Votes
21,966,944	3,185	4,439	—

No other matters were submitted for stockholder action.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 29, 2020

**Protagonist Therapeutics, Inc.**

By: /s/ Don Kalkofen  
Don Kalkofen  
Chief Financial Officer

---